AR027443A1 - MUTANTES DE EHV gM-NEGATIVOS - Google Patents

MUTANTES DE EHV gM-NEGATIVOS

Info

Publication number
AR027443A1
AR027443A1 ARP010100708A ARP010100708A AR027443A1 AR 027443 A1 AR027443 A1 AR 027443A1 AR P010100708 A ARP010100708 A AR P010100708A AR P010100708 A ARP010100708 A AR P010100708A AR 027443 A1 AR027443 A1 AR 027443A1
Authority
AR
Argentina
Prior art keywords
ehv
methods
viruses
refers
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ARP010100708A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Original Assignee
Boehringer Ingelheim Vetmedica GmbH
Boehringer Ingelheim Vetmedica de C V SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Vetmedica GmbH, Boehringer Ingelheim Vetmedica de C V SA filed Critical Boehringer Ingelheim Vetmedica GmbH
Publication of AR027443A1 publication Critical patent/AR027443A1/es
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/27—Equine rhinopneumonitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16722—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16741—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16743—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se refiere a virus herpes equinos (EHV), en donde la proteína gM está esencialmente ausente, o está modificada y no es funcional con respecto a sucapacidad inmunomoduladora. Aspectos adicionales de la invencion se refieren a ácidos nucleicos que codi fican dichos virus, a composiciones farmacéuticas quecomprenden a estos virus o a ácidos nucleicos y a sus usos. Se refiere también a métodos para mejorar la respuesta inmunitaria inducida por una vacuna de EHVfrente a infecciones de EHV de tipo salv aje, a métodos para la profilaxis y el tratamiento de infecciones de EHV y a métodos para distinguir animalesinfestados con EHV de tipo salvaje de animales tratados con EHVs de acuerdo con la invencion.
ARP010100708A 2000-02-17 2001-02-16 MUTANTES DE EHV gM-NEGATIVOS Pending AR027443A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP00103241A EP1129722A1 (en) 2000-02-17 2000-02-17 gM-negative EHV-mutants

Publications (1)

Publication Number Publication Date
AR027443A1 true AR027443A1 (es) 2003-03-26

Family

ID=8167872

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100708A Pending AR027443A1 (es) 2000-02-17 2001-02-16 MUTANTES DE EHV gM-NEGATIVOS

Country Status (24)

Country Link
US (3) US6703231B2 (es)
EP (2) EP1129722A1 (es)
JP (1) JP5177927B2 (es)
KR (1) KR100845192B1 (es)
CN (2) CN100378216C (es)
AR (1) AR027443A1 (es)
AT (1) ATE422363T1 (es)
AU (2) AU2001248313B2 (es)
BR (1) BR0108442A (es)
CA (1) CA2399846C (es)
CO (1) CO5280143A1 (es)
CY (1) CY1109023T1 (es)
CZ (1) CZ303657B6 (es)
DE (1) DE60137621D1 (es)
DK (1) DK1259258T3 (es)
ES (1) ES2322236T3 (es)
HK (1) HK1052462A1 (es)
HU (1) HU228217B1 (es)
MX (1) MXPA02008009A (es)
NZ (1) NZ521365A (es)
PL (1) PL210441B1 (es)
PT (1) PT1259258E (es)
UY (1) UY26588A1 (es)
WO (1) WO2001060403A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1129722A1 (en) * 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
US7906311B2 (en) 2002-03-20 2011-03-15 Merial Limited Cotton rat lung cells for virus culture
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
DE10233064A1 (de) * 2002-07-19 2004-02-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-Mutanten ohne heterologe Elemente
EP1394258A1 (en) * 2002-08-30 2004-03-03 Geneart GmbH Non-human herpesviruses as vectors
JP2022523564A (ja) 2019-03-04 2022-04-25 アイオーカレンツ， インコーポレイテッド 機械学習を使用するデータ圧縮および通信

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731188A (en) * 1986-11-20 1998-03-24 Syntro Corporation Recombinant equine herpesviruses
US5674735A (en) 1990-07-06 1997-10-07 University Court Of The University Of Glasgow DNA encoding the EHV-4 gH or gC glycoprotein
GB9014950D0 (en) 1990-07-06 1990-08-29 Univ Glasgow Ehv-4 glycoprotein vaccine
DE4110962A1 (de) 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen
US6193983B1 (en) 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
ATE259417T1 (de) * 1992-06-01 2004-02-15 Univ Melbourne Immunologisches verfahren für die detektion von pferde-herpesvirus typ 1 und 4 glycoprotein g antikörper
US5853715A (en) 1996-08-16 1998-12-29 Bayer Corporation Cross-protective equine herpesvirus preparations and method of making and using the same
GB9625968D0 (en) 1996-12-13 1997-01-29 Univ Glasgow Vaccine
GB9626029D0 (en) 1996-12-14 1997-01-29 Univ Leeds EVH-1 vectors
AU758604B2 (en) 1998-07-31 2003-03-27 Intervet International B.V. Attenuated equine herpesvirus
HUP0202738A3 (en) 1999-09-10 2003-12-29 Akzo Nobel Nv Equine herpes virus temperature sensitive mutant and live vaccine thereof
EP1129722A1 (en) 2000-02-17 2001-09-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-mutants
NZ523772A (en) 2000-07-27 2004-06-25 Res Corp Technologies Inc Vaccines for equine herpesvirus type-1: viruses harboring mutations within the immediate early gene
AR040601A1 (es) 2002-07-19 2005-04-13 Boehringer Ingelheim Vetmed Mutantes ehv negativos de gm sin elementos heterologos
DE10233064A1 (de) 2002-07-19 2004-02-05 Boehringer Ingelheim Vetmedica Gmbh gM-negative EHV-Mutanten ohne heterologe Elemente

Also Published As

Publication number Publication date
AU4831301A (en) 2001-08-27
JP5177927B2 (ja) 2013-04-10
KR20030032914A (ko) 2003-04-26
CZ20022809A3 (cs) 2003-01-15
CA2399846A1 (en) 2001-08-23
BR0108442A (pt) 2003-03-25
CN1400907A (zh) 2003-03-05
UY26588A1 (es) 2001-09-28
DK1259258T3 (da) 2009-06-02
CZ303657B6 (cs) 2013-02-06
ES2322236T3 (es) 2009-06-18
PT1259258E (pt) 2009-03-18
CN100378216C (zh) 2008-04-02
MXPA02008009A (es) 2003-01-28
PL210441B1 (pl) 2012-01-31
CN101230336A (zh) 2008-07-30
HK1052462A1 (zh) 2003-09-19
EP1129722A1 (en) 2001-09-05
US20030198650A1 (en) 2003-10-23
EP1259258B1 (en) 2009-02-11
WO2001060403A1 (en) 2001-08-23
US20040063095A1 (en) 2004-04-01
US6703231B2 (en) 2004-03-09
JP2003522542A (ja) 2003-07-29
EP1259258A1 (en) 2002-11-27
PL357019A1 (en) 2004-07-12
US8017317B2 (en) 2011-09-13
HUP0204446A2 (en) 2003-05-28
CO5280143A1 (es) 2003-05-30
CA2399846C (en) 2011-06-14
DE60137621D1 (de) 2009-03-26
NZ521365A (en) 2004-07-30
KR100845192B1 (ko) 2008-07-10
HUP0204446A3 (en) 2010-01-28
HU228217B1 (en) 2013-02-28
US7309598B2 (en) 2007-12-18
AU2001248313B2 (en) 2006-03-02
CY1109023T1 (el) 2014-07-02
ATE422363T1 (de) 2009-02-15
US20080160046A1 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2001089559A3 (en) Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
NO944245L (no) Rekombinante DNA-molekyler som koder for aminopeptidase-enzymer og deres anvendelse ved fremstilling av vaksiner mot helmintinfeksjoner
EA200100302A1 (ru) Способы и композиции для протективной и терапевтической генетической иммунизации
BRPI0113155C1 (pt) métodos para produção de uma vacina para hepatite b e de um antígeno de superfície para hepatite b
MXPA05005202A (es) Vacuna.
ATE517184T1 (de) Hcv ns3/4a kodierende nukleinsäure
CY1109023T1 (el) Gm-αρνητικα μεταλλαγματα ehv
CY1109206T1 (el) gM- ΑΡΝΗΤΙΚΟΙ EHV-ΜΕΤΑΛΛΑΚΤΕΣ ΧΩΡΙΣ ΕΤΕΡΟΛΟΓΑ ΣΤΟΙΧΕΙΑ
DE50010240D1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
BR0206112A (pt) Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
AR040601A1 (es) Mutantes ehv negativos de gm sin elementos heterologos
Lorenzo et al. Protection against Rift Valley fever virus infection in mice upon administration of interferon-inducing RNA transcripts from the FMDV genome
AR005750A1 (es) Composicion farmaceutica para tratar o prevenir infecciones con zoster en personas infectadas con el virus de varicela zoster y procedimiento para preparar dicha composicion
ES2155510T3 (es) Vacuna mejorada para la inmunizacion contra infecciones por el virus tbe y procedimiento para su preparacion.
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
WO2004082596A3 (en) Yersinia species compositions
ATE318321T1 (de) Leporipox-basierende vektorvakzine
ES2077017T3 (es) Vacuna contra el virus de la bronquitis infecciosa.
BR0110791A (pt) Composição, métodos para induzir uma resposta imune em um indivìduo contra um imunogene, para modular o sistema imune de um indivìduo e para imunizar um indivìduo contra um patógeno, vacina recombinante, e patógeno atenuado vivo
BR9708188A (pt) Imunidade a espécies de tripanosomatidae.
RU2004104357A (ru) Вакцинный состав, потенцированный комбинацией днк и антигена
RU2020100038A (ru) Материалы и методы, используемые для лечения респираторных заболеваний у собак
ES2171360A1 (es) Vacuna para la proteccion de animales frente a la leishmania.
TH92454B (th) วัคซีนที่ใช้ทางปาก, วิธีการเตรียมของมันและการใช้วัคซีนเหล่านี้

Legal Events

Date Code Title Description
FG Grant, registration
FG Grant, registration